Data published to the New England Journal of Medicine in late April showed Black and Latinx adults with moderate to severe asthma benefitted from the addition of a patient-directed, quick-reliever provisional inhaled glucocorticoid therapy along with their usual care.
The findings contribute to the prospect of implementing simpler care strategies for patients with difficult-to-control asthma, as well as feasible steps toward reducing asthma outcome disparities among people of color.
This May, during Asthma Awareness Month, the concept of PREPARE trial and its leading investigators headline a comprehensive discussion around mitigating key challenges in the chronic respiratory disease.
The newest episode of Lungcast features PREPARE investigators Elliot Israel, MD, of Harvard Medical School and Brigham and Women’s Hospital, and Juan Carlos Cardet, MD, MPH, of the University of South Florida Morsani College of Medicine.
Along with host Albert Rizzo, MD, chief medical officer of the American Lung Association (ALA), the research team discussed guideline-supported SMART strategy, the role of COVID in current asthma risks, and their own research into the disparate medical and financial impacts of asthma on the US patient population.
Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.
Subscribe or listen to Lungcast on your favorite platforms: